ARTV (Artiva Biotherapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Artiva Biotherapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-14.71 Mil. Artiva Biotherapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Artiva Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Artiva Biotherapeutics's current FCF Yield % is -72.32%.

The historical rank and industry rank for Artiva Biotherapeutics's FCF Margin % or its related term are showing as below:

ARTV' s FCF Margin % Range Over the Past 10 Years
Min: -22180.88 Med: -1004.55 Max: -151.34
Current: -22180.88

During the past 6 years, the highest FCF Margin % of Artiva Biotherapeutics was -151.34%. The lowest was -22180.88%. And the median was -1004.55%.

ARTV's FCF Margin % is ranked worse than
94.6% of 1018 companies
in the Biotechnology industry
Industry Median: -139.165 vs ARTV: -22180.88

Artiva Biotherapeutics FCF Margin % Historical Data

The historical data trend for Artiva Biotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics FCF Margin % Chart

Artiva Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-850.55

-1,158.55

-151.34

-22,180.88

Artiva Biotherapeutics Quarterly Data
	Sep20	Dec20	Mar21	Sep21	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial										-481.32	-6,017.53	-	-	-

Competitive Comparison of Artiva Biotherapeutics's FCF Margin %

For the Biotechnology subindustry, Artiva Biotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artiva Biotherapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Artiva Biotherapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Artiva Biotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Artiva Biotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-55.674	/	0.251
	=	-22,180.88 %

Artiva Biotherapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-14.714	/	0
	=	%

Artiva Biotherapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.artivabio.com

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.